About this trial
The aim of this study is the clinical and radiographic evaluation of (Platelet-Rich Fibrin (PRF) versus Mineral Trioxide Aggregate (MTA) in indirect pulp capping when used with deep carious molars over 1 year follow up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
o Patients with asymptomatic deep carious molars.
Patients with clinically and radiographically confirmed deep carious lesions that do not exhibit spontaneous pain.
Permanent molars only.
Teeth with intact or minimally restored occlusal surfaces (i.e., no extensive restorations or fractures).
Disqualifiers
o Patients with systemic conditions affecting bone or tissue healing (e.g., uncontrolled diabetes, osteoporosis, immunosuppressed conditions).
Pregnant or lactating women (if applicable to your study).
Teeth with pulp exposure or necrotic pulp.
Presence of symptomatic irreversible pulpitis (e.g., spontaneous pain, lingering pain).
Trial design
Parallel
Treatments tested in this trial
MTA
DrugThe indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above
PRF
Biological/VaccineThe indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above
Treatment groups
Trial outcomes
Primary outcomes
Pulp sensibility using cold test
clinical finding of the investigated tooth measured with binary (yes or no)
Secondary outcomes
Radiographic finding
Digital Periapical using paralleling technique (Dentin bridge measurement in mm using digital radiographic ruler)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: